A European Multicenter, Randomized, Parallel-group Study to Evaluate the Safety and Efficacy/Performance of DAV132 in Hospitalized Patients at High Risk for Clostridium Difficile Infection and Who Receive Fluoroquinolones for the Treatment of Acute Infections
Latest Information Update: 17 Jan 2022
At a glance
- Drugs DAV 132 (Primary) ; Fluoroquinolones
- Indications Infections
- Focus Adverse reactions
- Acronyms SHIELD
- Sponsors Da Volterra
Most Recent Events
- 17 Jan 2022 New trial record
- 10 Jan 2022 According to Da Volterra media release, positive results from this trial published in the Journal of Antimicrobial Chemotherapy (JAC).
- 10 Jan 2022 Results published in the Media Release